BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15368961)

  • 1. [A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers].
    Feunteun J
    J Soc Biol; 2004; 198(2):123-6. PubMed ID: 15368961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
    Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
    Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
    Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
    Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.
    Buekers TE; Lallas TA; Buller RE
    Gynecol Oncol; 2000 Mar; 76(3):418-22. PubMed ID: 10684722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
    Cavalli LR; Singh B; Isaacs C; Dickson RB; Haddad BR
    Cancer Genet Cytogenet; 2004 Feb; 149(1):38-43. PubMed ID: 15104281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
    King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
    Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
    Berchuck A; Heron KA; Carney ME; Lancaster JM; Fraser EG; Vinson VL; Deffenbaugh AM; Miron A; Marks JR; Futreal PA; Frank TS
    Clin Cancer Res; 1998 Oct; 4(10):2433-7. PubMed ID: 9796975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian tumors.
    van der Looij M; Papp J; Sztán M; Pulay T; Elfadil I; Besznyak I; Tóth J; Devilee P; Oláh E
    Int J Oncol; 2001 Apr; 18(4):775-80. PubMed ID: 11251173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method].
    Byrski T
    Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
    Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T
    Oncogene; 2002 Aug; 21(33):5097-107. PubMed ID: 12140760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.
    Neuhausen SL; Marshall CJ
    Cancer Res; 1994 Dec; 54(23):6069-72. PubMed ID: 7954448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells.
    Sirchia SM; Ramoscelli L; Grati FR; Barbera F; Coradini D; Rossella F; Porta G; Lesma E; Ruggeri A; Radice P; Simoni G; Miozzo M
    Cancer Res; 2005 Mar; 65(6):2139-46. PubMed ID: 15781624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
    Johannsdottir HK; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Johannsson OT; Heikkilä P; Egilsson V; Olsson H; Borg A; Nevanlinna H; Barkardottir RB
    Anticancer Res; 2004; 24(5A):2681-7. PubMed ID: 15521105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.